Vaxcyte's Insider Exodus: Why CEO Sales Cloud a Bullish Biotech Narrative

Related Articles

Guidewire Software's Insider Exodus: Why Executive Sales Cloud a Bullish Outlook

1 months ago

MicroStrategy's Insider Exodus: Why Director Sales Undermine the Bitcoin Narrative

1 months ago

Adaptive Biotechnologies: Why Executive Sales Cloud a Biotech Growth Story

2 months ago

Fastly's Insider Exodus: Why CEO Sales Signal Caution Despite AI Hype

1 months ago

Category

You may also like

Stock News•5 days ago

A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know

Vaxcyte executive Jim Wassil cashed options struck at $5.35, realizing about $378,000 at $61.12 per share, equal to 4% of his prior stake. The sale may signal reduced insider conviction, though long-t...

PCVX

Share

Stock News•2 months ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Big Pharma is spending at a pace not seen since 2019 to replace ~$300B in drugs losing patent protection, fueling biotech acquisitions.

ABBV

Share

Stock News•2 months ago

Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook

A Corcept insider sold shares for $1.9M at ~$93.13 each on July 7, after an FDA approval and a $1.05B outlook.

CORT

Share